Literature DB >> 26467074

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

M Nosè1, I Bighelli1, M Castellazzi1, G Martinotti2, G Carrà3, C Lucii4, G Ostuzzi1, F Sozzi1, C Barbui1.   

Abstract

AIMS: In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.
METHOD: The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by collecting data under ordinary circumstances. During a three-month period, a consecutive unselected series of both in- and out-patients were enrolled if they performed an ECG during the recruitment period and were receiving psychotropic drugs on the day ECG was recorded.
RESULTS: During the recruitment period a total of 2411 patients were included in the study. The prevalence of QTc prolongation ranged from 14.7% (men) and 18.6% (women) for the cut-off of 450 ms, to 1.26% (men) and 1.01% (women) for the cut-off of 500 ms. In the multivariate model conducted in the whole sample of patients exposed to psychotropic drugs, female sex, age, heart rate, alcohol and/or substance abuse, cardiovascular diseases and cardiovascular drug treatment, and drug overdose were significantly associated with QTc prolongation. In patients exposed to antipsychotic drugs, polypharmacy was positively associated with QTc prolongation, whereas use of aripiprazole decreased the risk. In patients exposed to antidepressant drugs, use of citalopram, citalopram dose and use of haloperidol in addition to antidepressant drugs, were all positively associated with QTc prolongation.
CONCLUSIONS: The confirmation of a link between antipsychotic polypharmacy and QTc prolongation supports the current guidelines that recommend avoiding the concurrent use of two or more antipsychotic drugs, and the confirmation of a link between citalopram and QTc prolongation supports the need for routine QTc monitoring. The relatively low proportion of patients with QTc prolongation not only suggests compliance with current safety warnings issued by regulatory authorities, but also casts some doubts on the clinical relevance of QTc prolongation related to some psychotropic drugs.

Entities:  

Keywords:  Antidepressant; adverse effect; antipsychotic; psychotropic drugs

Mesh:

Substances:

Year:  2015        PMID: 26467074      PMCID: PMC7137657          DOI: 10.1017/S2045796015000906

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  20 in total

1.  A simple approach to manage dosages in drug-epidemiology research.

Authors:  Michela Nosè; Corrado Barbui
Journal:  Epidemiol Psichiatr Soc       Date:  2008 Jul-Sep

2.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

3.  Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.

Authors:  Scott R Beach; William J Kostis; Christopher M Celano; James L Januzzi; Jeremy N Ruskin; Peter A Noseworthy; Jeff C Huffman
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

4.  Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation.

Authors:  Tsuneaki Sadanaga; Fumiko Sadanaga; Hiroshi Yao; Masatoshi Fujishima
Journal:  J Electrocardiol       Date:  2004-10       Impact factor: 1.438

Review 5.  Antipsychotics and QT prolongation.

Authors:  D M Taylor
Journal:  Acta Psychiatr Scand       Date:  2003-02       Impact factor: 6.392

6.  QTc interval in a sample of long-term schizophrenia inpatients.

Authors:  Ramón Ramos-Ríos; Manuel Arrojo-Romero; Eduardo Paz-Silva; Fernando Carballal-Calvo; José L Bouzón-Barreiro; Jorge Seoane-Prado; Rosario Codesido-Barcala; Alicia Crespí-Armenteros; Ramón Fernández-Pérez; Javier D López-Moríñigo; Ignacio Tortajada-Bonaselt; Francisco J Diaz; Jose de Leon
Journal:  Schizophr Res       Date:  2010-01       Impact factor: 4.939

Review 7.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 8.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

Authors:  Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2013-06-27       Impact factor: 79.321

9.  QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study.

Authors:  Ingrid M M van Haelst; Wilton A van Klei; Hieronymus J Doodeman; Miriam J Warnier; Marie L De Bruin; Cor J Kalkman; Toine C G Egberts
Journal:  J Clin Psychiatry       Date:  2014-01       Impact factor: 4.384

10.  QT interval and antidepressant use: a cross sectional study of electronic health records.

Authors:  Victor M Castro; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Jane L Erb; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis
Journal:  BMJ       Date:  2013-01-29
View more
  16 in total

1.  Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.

Authors:  Gudrun Hefner; Martina Hahn; Christoph Hiemke; Sermin Toto; Jan Wolff; Sibylle C Roll; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2021-01-08       Impact factor: 3.575

2.  Antipsychotic drug exposure and risk of myocardial infarction.

Authors:  C Barbui; C Gastaldon; D Papola; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2016-11-22       Impact factor: 6.892

3.  Medicine-based evidence: the case of antidepressants in patients with coronary artery disease.

Authors:  C Barbui; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2018-07-30       Impact factor: 6.892

4.  QTc dispersion and interval changes in drug-free borderline personality disorder adolescents.

Authors:  Monica Bomba; Franco Nicosia; Anna Riva; Fabiola Corbetta; Elisa Conti; Francesca Lanfranconi; Lucio Tremolizzo; Renata Nacinovich
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-05-14       Impact factor: 4.785

5.  Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors.

Authors:  Teodora Andric; Karl Winckel; Timothy David Tanzer; Samantha Hollingworth; Lesley Smith; Katherine Isoardi; Olivier Tan; Dan Siskind
Journal:  Ther Adv Psychopharmacol       Date:  2022-06-16

6.  Corrected QT Interval and Methadone Dose and Concentrations in Pregnant and Postpartum Women.

Authors:  Debra L Bogen; Barbara H Hanusa; James M Perel; Frederick Sherman; Marla A Mendelson; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

Review 7.  Antidepressants for the treatment of depression in people with cancer.

Authors:  Giovanni Ostuzzi; Faith Matcham; Sarah Dauchy; Corrado Barbui; Matthew Hotopf
Journal:  Cochrane Database Syst Rev       Date:  2018-04-23

8.  Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

Authors:  Jan Wolff; Pamela Reißner; Gudrun Hefner; Claus Normann; Klaus Kaier; Harald Binder; Christoph Hiemke; Sermin Toto; Katharina Domschke; Michael Marschollek; Ansgar Klimke
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

9.  Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval.

Authors:  Corrado Barbui; Irene Bighelli; Giuseppe Carrà; Mariasole Castellazzi; Claudio Lucii; Giovanni Martinotti; Michela Nosè; Giovanni Ostuzzi
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.

Authors:  Andreas D Meid; Irene Bighelli; Sarah Mächler; Gerd Mikus; Giuseppe Carrà; Mariasole Castellazzi; Claudio Lucii; Giovanni Martinotti; Michela Nosè; Giovanni Ostuzzi; Corrado Barbui; Walter E Haefeli
Journal:  Ther Adv Psychopharmacol       Date:  2017-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.